REDWOOD CITY, Calif., Dec. 8 Genomic Health,Inc. (Nasdaq: GHDX) today announced the appointment of Ginger L. Graham to itsboard of directors. Ms. Graham is the former President and CEO of AmylinPharmaceuticals, Inc.; a biopharmaceutical company dedicated to developinginnovative medicines to improve the lives of people with diabetes and obesity.Prior to Amylin, Ms. Graham served as Group Chairman, Office of the President,for Guidant Corporation, a cardiovascular medical device manufacturer, andheld a number of management positions at Eli Lilly and Company, a globalpharmaceutical company.
"Ginger brings a wealth of industry leadership experience to GenomicHealth's board of directors, with expertise in developing and commercializingsuccessful products for pharmaceutical and medical device companies," saidRandy Scott, Ph.D., chairman and CEO of Genomic Health. "Her appointment comesat an opportune time as we continue to expand our commercial efforts outsideof the United States and invest in our product pipeline, as part of ourmission to make individualized treatment standard practice for all cancerpatients."
Ms. Graham received a Bachelor of Science in agricultural economics fromthe University of Arkansas. She also holds a Master of Business Administrationfrom Harvard University.
About Oncotype DX(R)
Oncotype DX is the first and only multi-gene expression test commerciallyavailable that has clinical evidence validating its ability to predict thelikelihood of chemotherapy benefit as well as recurrence in early-stage breastcancer. Additionally, the test report provides quantitative scores for certainindividual genes. Oncotype DX has been extensively evaluated in elevenclinical studies involving more than 4,000 breast cancer patients, including alarge validation study published in The New England Journal of Medicine and achemotherapy benefit study published in the Journal of Clinical Oncology. Todate, 7,500 physicians have ordered more than 75,000 tests, and both Medicareand private health plans covering approximately 90 percent of U.S. insuredlives provide reimbursement for Oncotype DX through contracts, agreements andpolicy decisions. Both the American Society of Clinical Oncology (ASCO) andthe National Comprehensive Cancer Network recommend the use of Oncotype DX forpatients with node-negative breast cancer that is estrogen-receptor positiveand/or progesterone-receptor positive. For more information about Oncotype DX,please visit http://www.oncotypedx.com.
About Genomic Health
Genomic Health, Inc. (Nasdaq: GHDX) is a life science company focused onthe development and commercialization of genomic-based clinical laboratoryservices for cancer that allow physicians and patients to make individualizedtreatment decisions. In 2004, Genomic Health launched its first test, OncotypeDX(R), which has been shown to predict the likelihood of breast cancerrecurrence and the likelihood of chemotherapy benefit in a large portion ofearly-stage breast cancer patients. The company was founded in 2000 and islocated in Redwood City, California. For more information, please visithttp://www.genomichealth.com.
This press release contains forward-looking statements within the meaningof the Private Securities Litigation Reform Act of 1995, including statementsrelating to the company's mission to make individualized treatment standardpractice for cancer patients, the ability of the company to continue to expandits commercial efforts outside of the United States and the ability of thecompany to continue to invest in its product pipeline. These risks anduncertainties include, but are not limited to: the results of additionalclinical studies; the applicability of clinical study results to actualoutcomes; the risk that we may not obtain or maintain sufficient levels ofreimbursement for our test; the risks and uncertainties associated with theregulation of our tests by FDA; our ability to develop new tests; our abilityto obtain capital when needed; our history of operating losses and the otherrisks set forth in our filings with the Securities and Exchange Commission,including the risks set forth in our Quarterly Report on Form 10-Q for thethree-month period ended September 30, 2008. These forward-looking statementsspeak only as of the date hereof. Genomic Health disclaims any obligation toupdate these forward-looking statements.
NOTE: The Genomic Health logo, Oncotype, Oncotype DX and Recurrence Scoreare trademarks or registered trademarks of Genomic Health, Inc. All othertrademarks and service marks are the property of their respective owners.
SOURCE Genomic Health, Inc.